Literature DB >> 769971

Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.

R O Johnson, G Metter, W Wilson, G Hill, E Krementz.   

Abstract

The major toxic effects of DTIC are nausea and vomiting, leukopenia, and thrombocytopenia. It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men. The addition of other drugs to DTIC therapy does not produce a higher response rate. Preliminary results indicate that as an adjuvant to standard surgical therapy DTIC does not appear beneficial to patients with a high risk for recurrence.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 769971

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  8 in total

Review 1.  The role of chemotherapy in the modern management of melanoma.

Authors:  Rebecca Jane Lee; Noor Ul-Ain-Tariq; Alberto Fusi; Samantha Bowyer; Paul Lorigan
Journal:  Melanoma Manag       Date:  2014-12-04

Review 2.  Cancer chemotherapy: past, present, and future--Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1984-08       Impact factor: 1.798

3.  Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.

Authors:  C I Falkson
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.

Authors:  P J Frosch; B M Czarnetzki; E Macher; E Grundmann; I Gottschalk
Journal:  J Cancer Res Clin Oncol       Date:  1979       Impact factor: 4.553

5.  A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.

Authors:  D R Adkins; R Irvin; J Kuhn; D H Boldt; G D Roodman; D Salzman; C Freytes; D D Von Hoff; C F LeMaistre
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

6.  Hepatic vascular lesions associated with dacarbazine treatment.

Authors:  M A Greenstone; P M Dowd; D P Mikhailidis; P J Scheuer
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

7.  [Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].

Authors:  H Voigt; J Caselitz; M Jänner
Journal:  Klin Wochenschr       Date:  1981-03-02

8.  Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.

Authors:  B J Foster; D R Newell; L A Gumbrell; K E Jenns; A H Calvert
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.